PURE Bioscience to Present at the Lippert/Heilshorn

Life Sciences & Medtech Virtual Conference on July 20

SAN DIEGO, CA, July 15, 2010 – PURE Bioscience (NASDAQ: PURE) today announced that President and CEO Michael L. Krall will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-line Forum on July 20, 2010 at 10:30 a.m. Eastern time.  The presentation will provide a corporate overview and discuss the Company’s growth strategy.

Interested parties can access a live audio webcast with slide presentation at www.purebio.com, or from the PrecisionIR site at http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=160292,

An archived presentation will be available for 30 days.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area).  Additional information on PURE is available at www.purebio.com.